Skip to main content
. 2016 Dec 29;58(1):81–91. doi: 10.1194/jlr.M069799

Fig. 1.

Fig. 1.

ASO-Fsp27 treatment reduces visceral adiposity without worsening hepatic steatosis in HFD-fed mice. A: Male C57BL/6 mice (4 weeks old, n = 6) were fed an HFD for 17 weeks, where the last five included treatment with ASO-ctrl or ASO-Fsp27 (25 mg/kg ip twice weekly; arrowheads). An age-matched control group of mice (n = 4) was kept on an ND. B: Body weight at time of euthanization. C: Food intake during the last 2 weeks. D: Representative macroscopic appearance of the left eWAT pad. E: Absolute and relative weight of eWAT. F: eWAT triacylglyceride (TAG) contents. G: Multilocular LDs (arrows) were recognizable only in ASO-Fsp27 eWAT sections stained with hematoxylin and eosin. Scale bar represents 100 μm. H: Relative eWAT Fsp27 mRNA expression. I: Representative macroscopic appearance of the livers. J: Absolute and relative liver weight. K: Hepatic TAG contents. L: Paraffin-embedded sections of livers stained with hematoxylin and eosin show HFD-induced cell ballooning and steatosis. Scale bar represents 100 μm. M: Relative hepatic Fsp27 mRNA expression. Data are shown as mean ± SEM. * P ≤ 0.05 and ** P ≤ 0.01, HFD vs. ND; ¶¶ P ≤ 0.01, ASO-Fsp27 vs. ASO-ctrl. These data are representative of two independent experiments.